Morphic Medical Welcomes New Additions to Board of Directors
Three New Members Bring Extensive Leadership and Industry Experience to Morphic MedicalBOSTON--(BUSINESS WIRE)--Morphic Medical, creator of the world’s first medical...
Healthcare
DeepSight™ Technology Introduces NeedleVue™ Solution: Revolutionizing the Future of Ultrasound-Guided Interventional Tool Guidance
SANTA CLARA, Calif., Nov. 13, 2023 /PRNewswire/ -- DeepSight™ Technology, a pioneering force in medical innovation, is thrilled to announce...
Partnership Between Florence Healthcare and WCG to Advance Site Enablement in Clinical Research
ATLANTA, GA and PRINCETON, NJ / ACCESSWIRE / November 13, 2023 / Florence Healthcare and WCG have announced a strategic...
Fusion Announces Scholarship for Nurses, Encouraging More Students to Choose Healthcare Professions
ELKHORN, NE / ACCESSWIRE / November 13, 2023 / Fusion has announced a new scholarship program, Compassion in Care -...
Inogen Announces Leadership Change with the Appointment of Kevin Smith as President and CEO
Seasoned Leader Brings More than Two Decades of Medical Device Experience and Proven Track Record of Driving Growth and Organizational...
Surescripts Health Information Network Submits Application to Become a Qualified Health Information Network
Surescripts leads nationwide interoperability, connecting more than 2 million care providers with virtually every American patient, supporting better informed careARLINGTON,...
US Med-Equip, Helping Healthcare Heroes Across the Country, Recognized as ‘Top Workplace’ Five Years Running
Hospital medical equipment rental and service partner continues expansion to meet extraordinary demand from for on-demand access to equipment as...
HeartSciences’ MyoVista® wavECGTM Selected for Heart Screening of Irish Garda National Police Officers
Southlake, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”),...
Healthcare Triangle Reports Third Quarter 2023 Results
PLEASANTON, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Healthcare Triangle, Inc. (Nasdaq: HCTI) (“HCTI” or the "Company"), a leader in...
IO Biotech Announces 2023 Third Quarter Results
Completed enrollment of 380 patients in pivotal Phase 3 trial of lead therapeutic cancer vaccine, IO102-IO103 in combination with KEYTRUDA®...
Comera Life Sciences Appoints Dorothy Clarke to Board of Directors
Dorothy Clarke Dorothy Clarke WOBURN, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a...
New Randomized Controlled Trial Demonstrates the Efficacy of Daxor’s BVA Guided-Care in Heart Failure Patients
Data From Study Funded by NIH Presented at the American Heart Association Annual Meeting Oak Ridge, TN, Nov. 13, 2023...
Immunovant to Present at Upcoming Investor Conferences
NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal...
MIMEDX to Participate in Upcoming Investor Conferences
MARIETTA, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that...
Head-to-head Trial of Prolonged-Release Oral Ketamine Formulation, KET01, and Intranasal SPRAVATO®, Finds Less Incidence of Dissociation or Cardiovascular Effects with Oral Treatment, at doses used for Treatment-Resistant Depression
Results Suggest Formulation Potentially Suitable for At-Home Administration Ketabon Also Releases In-Depth Data from Phase 2 KET01 Trial MUNICH, Germany,...
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights
-- BROADWAY Phase 3 trial enrollment completed; on-track to report topline data for Phase 3 BROOKLYN and BROADWAY trials in...
IO Biotech Appoints Helen Collins, MD, to its Board of Directors
NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating...
Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
Enrollment underway in Phase 1 trial with novel protease inhibitor CDI-988, the first potential dual coronavirus-norovirus oral antiviralDosing expected to...
VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
Transformative capital raise of $88.2 million from leading healthcare investors provides funding for BET inhibitor programs through the end of...
Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results
Phase 1 clinical trial of APG777, a fully optimized, subcutaneous, extended half-life anti-IL-13 antibody, initiated ahead of schedule with initial...